# Diabetes Mellitus, Type 2 FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/diabetes-mellitus-type-2

> 18 upcoming FDA catalysts in diabetes Mellitus, Type 2: cagrisema (NVO) on Jun to Sep 2027 (topline data readout); cagrisema (NVO) on June 2027 (primary completion); Wegovy (semaglutide, NVO) on Sep to Dec 2027 (topline data readout); Wegovy (semaglutide, NVO) on September 2027 (primary completion); and 14 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| September 19, 2025 | [NNC0519-0130 primary completion](https://sec-api.dev/pdufa/nnc0519-0130) | NVO | Diabetes Mellitus, Type 2 | completed | "NCT06326047 (A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Lower Blood Sugar in People With Type 2 Diabetes): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-09-19 (ACTUAL); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06326047)) |
| December 19, 2025 | [AZD5004 primary completion](https://sec-api.dev/pdufa/azd5004) | AZN | Diabetes Mellitus, Type 2 | completed | "NCT06579105 (Efficacy, Safety, and Tolerability of Once Daily Oral Administration of AZD5004 Versus Placebo for 26 Weeks in Adults With Type 2 Diabetes Mellitus.): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-12-19 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06579105)) |
| June 2, 2026 | [Wegovy (semaglutide) primary completion](https://sec-api.dev/pdufa/semaglutide) | NVO | Diabetes Mellitus, Type 2 | completed | "NCT06534411 (A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-06-02 (ACTUAL); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06534411)) |
| August 27, 2026 | [Retatrutide primary completion](https://sec-api.dev/pdufa/retatrutide) | LLY | Diabetes Mellitus, Type 2 | completed | "NCT06260722 (Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-08-27 (ACTUAL); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06260722)) |
| Aug to Nov 2026 | [Retatrutide topline data readout](https://sec-api.dev/pdufa/retatrutide) | LLY | Diabetes Mellitus, Type 2 | scheduled | "NCT06260722 (Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-08-27 (ACTUAL); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06260722)) |
| November 2026 | [LY3938577 primary completion](https://sec-api.dev/pdufa/ly3938577) | LLY | Diabetes Mellitus, Type 2 | scheduled | "NCT07215312 (A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-11 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07215312)) |
| Nov 2026 to Feb 2027 | [LY3938577 topline data readout](https://sec-api.dev/pdufa/ly3938577) | LLY | Diabetes Mellitus, Type 2 | scheduled | "NCT07215312 (A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-11 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07215312)) |
| Jun to Sep 2027 | [Cagrisema topline data readout](https://sec-api.dev/pdufa/cagrisema) | NVO | Diabetes Mellitus, Type 2 | scheduled | "NCT07817251 (Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-06-09 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07817251)) |
| June 2027 | [Cagrisema primary completion](https://sec-api.dev/pdufa/cagrisema) | NVO | Diabetes Mellitus, Type 2 | scheduled | "NCT07817251 (Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-06-09 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07817251)) |
| Sep to Dec 2027 | [Wegovy (semaglutide) topline data readout](https://sec-api.dev/pdufa/semaglutide) | NVO | Diabetes Mellitus, Type 2 | scheduled | "NCT07415954 (A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-09-03 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07415954)) |
| September 2027 | [Wegovy (semaglutide) primary completion](https://sec-api.dev/pdufa/semaglutide) | NVO | Diabetes Mellitus, Type 2 | scheduled | "NCT07415954 (A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-09-03 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07415954)) |
| Oct 2027 to Jan 2028 | [Wegovy (semaglutide) topline data readout](https://sec-api.dev/pdufa/semaglutide) | NVO | Diabetes Mellitus, Type 2 | scheduled | "NCT07668388 (A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-10-04 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07668388)) |
| October 2027 | [Wegovy (semaglutide) primary completion](https://sec-api.dev/pdufa/semaglutide) | NVO | Diabetes Mellitus, Type 2 | scheduled | "NCT07668388 (A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-10-04 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07668388)) |
| Nov 2027 to Feb 2028 | [Wegovy (semaglutide) topline data readout](https://sec-api.dev/pdufa/semaglutide) | NVO | Diabetes Mellitus, Type 2 | scheduled | "NCT03811561 (A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-11-07 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03811561)) |
| November 2027 | [Wegovy (semaglutide) primary completion](https://sec-api.dev/pdufa/semaglutide) | NVO | Diabetes Mellitus, Type 2 | scheduled | "NCT03811561 (A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-11-07 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03811561)) |
| Jun to Sep 2028 | [Zenagamtide topline data readout](https://sec-api.dev/pdufa/zenagamtide) | NVO | Diabetes Mellitus, Type 2 | scheduled | "NCT07931495 (A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2028-06-05 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07931495)) |
| June 2028 | [Zenagamtide primary completion](https://sec-api.dev/pdufa/zenagamtide) | NVO | Diabetes Mellitus, Type 2 | scheduled | "NCT07931495 (A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2028-06-05 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07931495)) |
| Jul to Oct 2028 | [Wegovy (semaglutide) topline data readout](https://sec-api.dev/pdufa/semaglutide) | NVO | Diabetes Mellitus, Type 2 | scheduled | "NCT07931599 (A Research Study Investigating How Well Zenagamtide at Lower Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide at Lower Dose Levels in People With Type 2 Diabetes Treated With Metformin, Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i), or Both): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2028-07-24 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07931599)) |
| July 2028 | [Wegovy (semaglutide) primary completion](https://sec-api.dev/pdufa/semaglutide) | NVO | Diabetes Mellitus, Type 2 | scheduled | "NCT07931599 (A Research Study Investigating How Well Zenagamtide at Lower Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide at Lower Dose Levels in People With Type 2 Diabetes Treated With Metformin, Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i), or Both): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2028-07-24 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07931599)) |
| Sep to Dec 2028 | [Maridebart cafraglutide topline data readout](https://sec-api.dev/pdufa/maridebart-cafraglutide) | AMGN | Diabetes Mellitus, Type 2 | scheduled | "NCT07866066 (Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 Diabetes): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-09-06 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07866066)) |
| September 2028 | [Maridebart cafraglutide primary completion](https://sec-api.dev/pdufa/maridebart-cafraglutide) | AMGN | Diabetes Mellitus, Type 2 | scheduled | "NCT07866066 (Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 Diabetes): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-09-06 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07866066)) |
| Sep to Dec 2029 | [Cagrisema (cagrilintide b and semaglutide i) topline data readout](https://sec-api.dev/pdufa/cagrisema-cagrilintide-b-and-semaglutide-i) | NVO | Diabetes Mellitus, Type 2 | scheduled | "NCT07282613 (A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-09-07 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07282613)) |
| September 2029 | [Cagrisema (cagrilintide b and semaglutide i) primary completion](https://sec-api.dev/pdufa/cagrisema-cagrilintide-b-and-semaglutide-i) | NVO | Diabetes Mellitus, Type 2 | scheduled | "NCT07282613 (A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-09-07 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07282613)) |
| March 2030 | [Foundayo (orforglipron calcium) primary completion](https://sec-api.dev/pdufa/orforglipron) | LLY | Diabetes Mellitus, Type 2 | scheduled | "NCT07668336 (A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-03 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07668336)) |
| Mar to Jun 2030 | [Foundayo (orforglipron calcium) topline data readout](https://sec-api.dev/pdufa/orforglipron) | LLY | Diabetes Mellitus, Type 2 | scheduled | "NCT07668336 (A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-03 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07668336)) |

## Drugs

- [NNC0519-0130](https://sec-api.dev/pdufa/nnc0519-0130) (NVO)
- [AZD5004](https://sec-api.dev/pdufa/azd5004) (AZN)
- [Wegovy (semaglutide)](https://sec-api.dev/pdufa/semaglutide) (NVO)
- [Retatrutide](https://sec-api.dev/pdufa/retatrutide) (LLY)
- [LY3938577](https://sec-api.dev/pdufa/ly3938577) (LLY)
- [Cagrisema](https://sec-api.dev/pdufa/cagrisema) (NVO)
- [Zenagamtide](https://sec-api.dev/pdufa/zenagamtide) (NVO)
- [Maridebart cafraglutide](https://sec-api.dev/pdufa/maridebart-cafraglutide) (AMGN)
- [Cagrisema (cagrilintide b and semaglutide i)](https://sec-api.dev/pdufa/cagrisema-cagrilintide-b-and-semaglutide-i) (NVO)
- [Foundayo (orforglipron calcium)](https://sec-api.dev/pdufa/orforglipron) (LLY)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/diabetes-mellitus-type-2.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Diabetes Mellitus, Type 2 FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/diabetes-mellitus-type-2

```bibtex
@misc{secapidev_indications_diabetes_mellitus_type_2_20261116,
  title        = {Diabetes Mellitus, Type 2 FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/diabetes-mellitus-type-2}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_diabetes_mellitus_type_2_20261116","title":"Diabetes Mellitus, Type 2 FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/diabetes-mellitus-type-2","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
